Detalhe da pesquisa
1.
Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
J Drugs Dermatol
; 19(3): 316-318, 2020 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32550686
2.
Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4.
Ann Rheum Dis
; 2017 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28794078
3.
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
Ann Rheum Dis
; 76(1): 51-57, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26150601
4.
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
Rheumatology (Oxford)
; 56(12): 2093-2101, 2017 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28968793
5.
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One.
BioDrugs
; 36(4): 431-436, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35696067
6.
Response to: 'Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required' by Moots et al.
Ann Rheum Dis
; 75(5): e25, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26888947
7.
Response to: 'Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences' by Shah.
Ann Rheum Dis
; 75(9): e61, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27435063
8.
Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al.
Ann Rheum Dis
; 75(7): e40, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27190097
9.
Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al.
Ann Rheum Dis
; 75(7): e38, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27147708
10.
Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo.
Ann Rheum Dis
; 75(10): e65, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27502892
11.
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis.
Arthritis Res Ther
; 22(1): 188, 2020 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32795341
12.
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis.
RMD Open
; 6(1)2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31958281
13.
Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis.
Curr Med Res Opin
; 35(3): 497-502, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30561229
14.
SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis.
Therap Adv Gastroenterol
; 12: 1756284819891081, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31839806
15.
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Arthritis Rheumatol
; 70(1): 40-48, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28950421
16.
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
Arthritis Rheumatol
; 70(6): 832-840, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439289